CHRONOS-3: Randomized Phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL).
Makaleler > Özet · 2021
Yazarlar: Matthew J. Matasar, Marcelo Capra, MUHİT ÖZCAN, Fangfang Lv, Wei Li, Eduardo Yanez, Katya Sapunarova, Tongyu Lin, Jie Jin, Wojciech Jurczak, Aryan Hamed, Ming-Chung Wang, Ross Baker, Igor Bondarenko, Qingyuan Zhang, Jifeng Feng, Klaus Geissler, Mihaela Lazaroiu, Güray SAYDAM, Arpad Szomor, Krimo Bouabdallah, Rinat Galiulin, Toshiki Uchida, Lidia Mongay Soler, Anjun Cao, Florian Hiemeyer, Aruna Mehra, Barrett H. Childs, Yuankai Shi, Pier Luigi Zinzani
CANCER RESEARCH, SCI Expanded İndekslerine Giren Dergi, Uluslararası, 2021, cilt 81